Meta Information
ID:cerebrolysin
Name:
Schema Version:2.4_uniform_evidence_2026_06_18
Created
2026-05-21T22:30:00Z
Model
phase-a-upgrade-claude-sonnet-4.6
Interactions
Target id:
/class/maois
Target name:
Monoamine Oxidase Inhibitors
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
The combination of Cerebrolysin and MAOIs can produce additive effects on the monoamine system, potentially leading to a dangerous hypertensive crisis.
Actionable advice:
Cerebrolysin and MAOIs should not be used concurrently; this combination is contraindicated.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/condition/renal-impairment
Target name:
Severe Renal Impairment
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Cerebrolysin's peptide components are cleared by the kidneys. In severe renal failure, these components can accumulate to potentially toxic levels.
Actionable advice:
Cerebrolysin should not be used in severe kidney disease or during dialysis.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
The effects of Cerebrolysin on fetal development are unknown. Due to the lack of safety data, its use is contraindicated during pregnancy.
Actionable advice:
Cerebrolysin should not be used during pregnancy or when planning to become pregnant.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/condition/lactation
Target name:
Breastfeeding (Lactation)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
It is not known whether the components of Cerebrolysin are excreted in human breast milk. To avoid potential risk to the infant, its use is contraindicated.
Actionable advice:
Cerebrolysin should not be used while breastfeeding.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/intervention/balanced-amino-acid-solutions
Target name:
Balanced Amino Acid Solutions for Infusion
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Mixing Cerebrolysin in the same infusion bag with balanced amino acid solutions can cause a pharmaceutical incompatibility, potentially inactivating the active peptides.
Actionable advice:
Cerebrolysin and amino acid solutions should never be mixed in the same IV infusion.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
informational_none
Target id:
/class/serotonergic-agents
Target name:
Serotonergic Medications (SSRIs, SNRIs, TCAs)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Cerebrolysin may have its own effects on neurotransmitter systems. Co-administration with other serotonergic drugs could theoretically increase the risk of adverse effects like serotonin syndrome.
Actionable advice:
This is best used with caution, and it is a good idea to monitor for symptoms like agitation or confusion when combined with serotonergic antidepressants.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
monitor
Target id:
/condition/seizure-disorder
Target name:
Seizure Disorder / Epilepsy
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Cerebrolysin may lower the seizure threshold in susceptible individuals, potentially interfering with the efficacy of anticonvulsant medications or provoking seizures.
Actionable advice:
This is best used with extreme caution in individuals with a history of seizures and only under specialist supervision.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
informational_none
Target id:
/intervention/iv-vitamins-minerals
Target name:
IV Vitamin and Mineral Infusions
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
To prevent potential pharmaceutical incompatibilities from pH changes or complexation, Cerebrolysin should not be mixed in the same infusion solution with vitamins or trace elements.
Actionable advice:
Administer Cerebrolysin through a separate IV line or flush the line thoroughly before and after administration.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
separate
Target id:
/procedure/neuro-rehabilitation-therapy
Target name:
Neuro-Rehabilitation (Physical, Occupational, Cognitive)
Severity:
moderate
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Cerebrolysin is believed to promote a state of enhanced neuroplasticity. This effect can significantly amplify the benefits of structured rehabilitation therapies aimed at recovering function.
Actionable advice:
For optimal results, Cerebrolysin treatment is best combined with a consistent and structured rehabilitation program.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
informational_none
Target id:
/intervention/high-dose-amino-acid-supplements
Target name:
High-Dose Amino Acid Supplements
Severity:
minor
Interaction type:
adverse
Nature:
temporal
Temporal spacing:
Hours before target:
2
Hours after target:
2
Description:
While not directly studied, high circulating levels of supplemental amino acids could theoretically compete with or alter the activity of the specific peptides in Cerebrolysin.
Actionable advice:
As a precaution, avoid taking high-dose amino acid supplements within 2 hours before or after a Cerebrolysin injection.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
separate
Target id:
/intervention/omega-3-dha
Target name:
Omega-3 DHA (Fish Oil, Algal Oil)
Severity:
minor
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
DHA is a critical structural component of neuronal membranes. Ensuring adequate DHA levels provides the necessary building blocks for the neuro-regenerative processes supported by Cerebrolysin.
Actionable advice:
Adequate daily intake of Omega-3 DHA through diet or supplementation may help during a Cerebrolysin course.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
informational_none
Target id:
/intervention/b-complex
Target name:
B-Complex Vitamins
Severity:
minor
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
B-vitamins (especially B6, B9, B12) are essential cofactors for neurotransmitter synthesis and neuronal metabolism, which can support the neurotrophic environment fostered by Cerebrolysin.
Actionable advice:
Optimal B-vitamin status is generally best maintained through a healthy diet or supplementation while using Cerebrolysin.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
informational_none